A potential game-changer for the millions suffering in silence! New scientific insights are offering a glimmer of hope for West Australians, and indeed up to 250,000 Australians nationwide, who grapple with the debilitating effects of chronic fatigue.
Scientists have uncovered compelling evidence pointing towards a specific cellular malfunction as a key player in Myalgic Encephalomyelitis, also known as Chronic Fatigue Syndrome (ME/CFS). This groundbreaking research, with contributions from Perth-based investigations, suggests a genetic anomaly affects how calcium enters the immune cells of individuals with ME/CFS.
But here's where it gets exciting (and potentially controversial): This discovery could pave the way for much-needed diagnostic tests and approved treatments for ME/CFS – both of which are currently lacking. For years, patients have navigated a complex and often isolating journey with limited medical understanding.
Dr. Natalie Eaton-Fitch from Griffith University explained it beautifully: Imagine your cell is like a house. The TRPM3 ion channels are like the doorways that allow calcium to enter. Calcium acts as the fuel for your cell's engine, ensuring it functions at its best. The research indicates that in people with ME/CFS, these crucial doorways might be faulty.
This isn't a new suspicion; Dr. Eaton-Fitch and her team have been investigating changes in these TRPM3 channels since 2016. Their latest study, a robust confirmation involving 78 participants (including those tested at the University of WA in Perth), solidifies their earlier findings. As Dr. Eaton-Fitch noted, "ME/CFS is so complicated. It’s very individual. A lot of people present differently. With this TRPM3 finding, we’ve looked at it in different cohorts, so we can say that this is a consistent finding across people with ME in Australia both genetically and functionally."
Emerge Australia, a leading support group, estimates that 1% of the Australian population, or approximately 250,000 people, are affected by ME/CFS. Alarmingly, a staggering 25% of these individuals, around 60,000 people, are so severely impacted they are housebound, bedridden, and entirely dependent on caregivers.
Often triggered by viral or bacterial infections, or even physical trauma, ME/CFS can profoundly alter a person's life. Dr. Eaton-Fitch is optimistic that the TRPM3 ion channel fault could serve as a biomarker, leading to a simple blood test for diagnosis.
And this is the part most people miss: Her team is on the cusp of a new clinical trial exploring low-dose naltrexone. This medication has shown promise in restoring TRPM3 ion function and alleviating ME/CFS symptoms in laboratory settings. While naltrexone is approved in Australia for other conditions, its use for ME/CFS is currently off-label. "We see from other publications that there’s a potential benefit in about 75 per cent of people with ME/CFS. What we’ve done in the laboratory is show restoration in all the participants that we’ve measured," Dr. Eaton-Fitch shared.
The ultimate goal? To gather enough evidence for low-dose naltrexone to be widely prescribed for ME/CFS and even be listed on the Pharmaceutical Benefits Scheme.
A Personal Journey:
Amanda Canzurlo, a 40-year-old singer from Perth, has lived with ME/CFS since she was 16, following a bout of glandular fever. Her experience paints a vivid picture of the illness's impact: "I was bedridden for an entire school term. Even simple tasks like showering or going to the bathroom would send my body into overdrive and require a full day of rest to recover." Her cognitive abilities were also affected, forcing her to rely on rote learning to compensate for memory struggles. Severe gut issues, a weakened immune system, and constant doctor visits were her reality for years.
"At the time — 24 years ago — there was very limited medical understanding of the condition, and working with a naturopath played a key role in helping me to rebuild my health," Amanda recalls. A Paleo-style diet and tailored supplements helped her regain enough strength to return to school, though persistent brain fog and fatigue remained.
Amanda likens the onset of her illness to "glandular fever lighting the fire and chronic fatigue keeping the embers burning." She explains, "I never feel as though my battery is at 100 per cent, and learning to manage that reality became an ongoing process throughout my 20s and 30s." Even a full-time job in her 20s proved unsustainable, with frequent naps during lunch breaks becoming a necessity.
Today, Amanda, performing under the stage name Bloom, is a successful touring artist. While she still experiences flare-ups, she manages a high-functioning level of mild ME/CFS by prioritizing rest, stress management, tailored exercise, and proper nutrition. Her recovery philosophy is about working with her body, not against it.
Now an ambassador for Emerge Australia, Amanda is dedicated to raising awareness and funds, aiming to collect $10,000 on her upcoming tour. She highlights a crucial point: "Research shows that 75 to 85 per cent of people living with ME/CFS are women. Looking at me, you wouldn’t necessarily know I have it, which is why it’s often called an invisible disease."
To those who are bedridden and unable to leave their homes, Amanda offers a message of solidarity: "Please know you are seen, and I’m committed to doing what I can to raise awareness, funds and advocate on your behalf."
What are your thoughts on this potential breakthrough? Do you believe the focus on cellular dysfunction is the right path for ME/CFS research? Share your opinions in the comments below!
